Drugs / pBI-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07454915 | Apr 2026 → Dec 2027 expected | cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection | PapiVax Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pBI-4 | “pBI-4 DNA vaccine (1.0 mg) administered by electroporation mediated intramuscular injection via the TriGrid Delivery System version 2.0 (TDS-IM v2.0)” NCT07454915 ↗ |
| Modality | Vaccine | “pBI-4 DNA vaccine” NCT07454915 ↗ |
| Route | Intramuscular | “administered by electroporation mediated intramuscular injection” NCT07454915 ↗ |